Market Overview

Vetr Upgrades Valeant After Price Dips

Share:

The Vetr crowd on Thursday upgraded its rating on Valeant Pharmaceuticals International, Inc. (NYSE: VRX), from 4 stars (Buy), issued two days ago, to 5 stars. Crowd sentiment at the time of the upgrade was largely positive, with 80 percent of Vetr user ratings bullish.

Share price In Valeant is back on the uptrend after dipping below $17 earlier in the week after hitting a four-month high of $17.75. The stock closed Thursday's session up, but still below that high at $17.65

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average price target on Valeant is up at $22.46, which is still below the average analyst price target of $24.58. Valeant Pharmaceuticals is a popular stock on Vetr as more than 2 percent of users are holding VRX in their watch-lists.

Latest Ratings for VRX

DateFirmActionFromTo
Jun 2018DowngradesBuyHold
Jun 2018UpgradesEqual-WeightOverweight
May 2018UpgradesNeutralBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: VetrUpgrades Price Target Crowdsourcing Analyst Ratings General

 

Related Articles (VRX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TSCOPiper SandlerMaintains119.0
UNPBMO CapitalMaintains200.0
UNPArgus ResearchMaintains205.0
ISRGJP MorganMaintains665.0
EHTHRBC CapitalMaintains132.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com